# Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

> clinical trial · VERIFIED · 2026-07-22

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Metastatic Nasopharyngeal Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: Metastatic Nasopharyngeal Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT06029270

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.